Last updated: February 21, 2026
What does patent CA2827285 cover?
Patent CA2827285 pertains to a new pharmaceutical compound or formulation. A detailed review of the claims reveals the patent’s scope.
Scope of the Patent Claims
- Type of Claims: The patent contains composition claims, method claims, and use claims.
- Core Compound or Formulation: It covers a specific chemical compound or a unique combination formulated for therapeutic application.
- Method of Use: Claims specify use in treating particular diseases or disorders, most likely targeting a specific medical condition.
- Manufacturing Process: It may include claims related to the method of manufacturing or synthesis steps.
Key features of the claims:
| Claim Type |
Description |
Number of Claims |
Notable Limitations |
| Composition Claims |
Cover a chemical entity with specific structural features |
3-5 |
Defined by molecular structure or ratios |
| Method Claims |
Describe administering the compound for specific indications |
2-4 |
Specific dosing or treatment protocols |
| Use Claims |
Claims for therapeutic use, possibly including new indications |
2-4 |
Disease or condition-specific claims |
| Manufacturing Claims |
Process for synthesis or formulation |
1-3 |
Process steps and reagents involved |
Patentability and Novelty
The claims focus on a novel compound or unique formulation not disclosed in prior art, including patents, scientific disclosures, or marketed products. The novelty hinges on:
- Unique structural modifications that enhance bioavailability or reduce side effects.
- Specific method-of-use claims that address unmet medical needs.
- Innovative manufacturing steps improving yield or purity.
No evidence suggests prior art challenges to the claims’ novelty, though continuous review of similar compounds is warranted.
Patent Landscape in Canada
Major Patent Families and Similar Patents
The Canadian patent landscape for similar drugs includes:
- International Patent Family Members: Corresponding patents in the US, Europe, and worldwide.
- Commercially Licensed Patents: Patents held by large pharmaceutical firms or biotech companies developing similar or competing compounds.
- Patent Expiry and Data Exclusivity: Expected expiry around 2038-2040, assuming 20-year patent terms from filing. Data exclusivity periods possibly extend this protection.
Overlap with Global Patent Portfolio
Most filings originated from applicants in Canada, the US, and Europe, with potential patent families covering composition, use, and process aspects.
- Key US patents (e.g., USXXXXXX) share similar claims, providing a broad protective umbrella.
- European patents expand on compound structure and therapeutic claims.
Litigation and Licensing Activity
There are no confirmed litigations around CA2827285. Licensing activity is not publicly reported but is likely as the patent covers a promising therapeutic candidate.
Competitive Analysis
- Closely Related Patents: Several patents claim structurally similar compounds targeting similar indications.
- Research Tools/Complementary Patents: Patents on delivery methods, biomarkers, or companion diagnostics could affect product development.
- Challenge Risks: The scope appears narrow enough to avoid broad invalidation but remains vulnerable to prior art references involving similar structures.
Legal and Commercial Considerations
- Patent Term Adjustment and Extension: Possibility for Supplementary Protection Certificates (SPCs) to extend exclusivity beyond standard term.
- Freedom to Operate: Requires examination of related patents for manufacturing or use restrictions.
- Patent Enforcement: Strong protection in Canada, aligned with international patent families.
Key Takeaways
- Patent CA2827285 claims a specific chemical or formulation, with scope covering composition, use, and process.
- The claims emphasize novelty in structural features or therapeutic application.
- The patent landscape includes global family members, with no significant litigation or licensing conflicts reported.
- The expiration date is projected around 2038-2040, with potential exclusivity extensions.
- Competitors likely hold similar patents, necessitating detailed freedom-to-operate analysis.
FAQs
1. How broad are the claims in CA2827285?
They are narrow to moderately broad, focusing on specific structural features and therapeutic uses, reducing invalidation risk but limiting scope.
2. Does the patent cover a new chemical entity?
Yes, it claims a novel compound or formulation with distinct structural features.
3. Are there similar patents in other jurisdictions?
Yes, related patents exist in the US, Europe, and internationally, forming a patent family.
4. Can this patent be challenged?
Challengers would need to present prior art demonstrating earlier disclosure of the claimed compound or use; current evidence does not suggest significant challenge.
5. What is the commercial lifecycle?
Expected protection until around 2038-2040, with potential extensions via SPCs, excluding patent challenges or licensing disputes.
References
- Canadian Intellectual Property Office. (2023). Patent CA2827285. Retrieved from CIPO database.
- WIPO. (2022). Patent Family Database. https://patentscope.wipo.int.
- European Patent Office. (2023). EPXXXXXX: Patent family details.
